DDInter112 DDInter782
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Aprepitant {u} (Compound) resembles {v} (Compound) Fosaprepitant
Aprepitant {u} (Compound) binds {v} (Gene) CYP1A2
Aprepitant {u} (Compound) palliates {v} (Disease) colon cancer
Aprepitant {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Aprepitant {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Aprepitant {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Aprepitant (Compound) resembles Fosaprepitant (Compound)
Aprepitant (Compound) binds CYP1A2 (Gene)
Aprepitant (Compound) palliates colon cancer (Disease)
Aprepitant (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Aprepitant (Compound) causes Myocardial infarction (Side Effect)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Citalopram
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Aprepitant may lead to a major life threatening interaction when taken with Deflazacort